Therapy for Women with HER2- Breast Cancer ASCO Guideline

Therapy for Women with HER2- Breast Cancer Home
Creado por Kaitlin Einhaus, modificado por última vez por Shannon McKernin el oct 10, 2014
This is an original JCO publication from 2014. Please visit the JCO website to access the full article.
________________________________________
Chemo- and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
________________________________________

Guideline Question
• This clinical practice guideline addresses the following four questions:

1. What are the indications for chemotherapy versus endocrine therapy in ER-positive first relapse metastatic breast cancer?

2. Is there an optimal first-line chemotherapy and/or targeted therapy regimen for patients with HER2-negative advanced breast cancer?
A. What is the optimal timing, dose, schedule, and duration?
B. Is there evidence to prefer single agent versus combination therapy?
C. Should first-line treatment vary by hormone receptor status, tumor subtypes (eg, luminal A v luminal B v triple negative) or clinical characteristics of the patient or tumor(s) (eg, site[s] or extent of metastasis, prior treatment, performance status and presence or absence of symptoms or immediately life-threatening disease)?

3. Is there an optimal second- or greater-line chemotherapy and/or targeted therapy regimen?
A. What are the optimal timing, doses, schedules, and durations?
B. Is there evidence to prefer single agent versus combination therapy?
C. Should treatment regimen vary by tumor subtypes or clinical characteristics?

4. At what point should anticancer therapy be discontinued?
A. Is there evidence to prefer maintenance versus interrupted therapy?
Target Population
• Women with advanced breast cancer (locally advanced/nonresectable or metastatic disease treated with noncurative intent). HER2-negative status is not an eligibility criterion for the systematic review, and for many patients in the trials reviewed, HER2 status was not given.

Target Audience
• This Clinical Practice Guideline is targeted to both health care providers (including primary care physicians, specialists, nurses, social workers, and any other relevant member of a comprehensive multidisciplinary cancer care team) and patients.

Methods
• An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature.

Recommendations
• See Summary of Recommendations Table below


Additional Resources
• More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about evidence quality and strength of recommendations, slide sets, and resources, is available at www.asco.org/guidelines/ABC_HER2-negative_chemo. Patient information is available at www.cancer.net.
• * Criteria for ratings of clinical benefits, harms, strength of evidence, and strength of recommendations are shown in the Methodology Supplement.

SUMMARY OF RECOMMENDATIONS

Recommendation 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard first-line treatment for advanced/metastatic breast cancer patients with hormone receptor positive disease, except for immediately life threatening disease or if there is concern regarding endocrine resistance (see companion ASCO guideline 1-18: Endocrine therapy for hormone-receptor positive advanced breast cancer, in development including consideration of hormonal therapy combination treatments)

Qualifying statement: It should be noted that the basis for this recommendation is the relative likelihood of response to chemotherapy versus endocrine therapy and not the rapidity of response, for which there are no good data The main benefit is less toxicity and better quality of life for the patient associated with endocrine therapy compared with chemotherapy (potential benefit: high). The harm is that metastatic disease could progress rapidly and prove fatal if there is no response, but the risk of this is low (potential harm: low).
Intermediate, based on the NCCC systematic review
Strong, supported by the evidence and expert consensus

Recommendation 2: Sequential single agent chemotherapy rather than combination therapy should be offered, although combination regimens may be considered for immediately life-threatening disease where time may allow only one potential chance for therapy.
The benefit is less toxicity and better quality of life (potential benefit: high). The potential harm is for rapidly progressing, life-threatening disease to escape control if response to a single agent isn’t achieved (potential harm: high).
The main benefit is there is less toxicity and better quality of life for the patient associated with sequential single agent chemotherapy compared with combination chemotherapy (potential benefit: high).
The harm is that metastatic disease could progress rapidly if there is no response, but the risk of this is low (potential harm: low).
High, including a large RCT
Strong

Recommendation 3: With regard to targeted agents, the role of bevacizumab is controversial and this therapy should only be considered (where available) with single-agent chemotherapy when there is immediately life-threatening disease or severe symptoms, in view of improved response rates (similar to Recommendation 2 regarding the use of combination chemotherapy).
It is recognized that there is not currently an approved indication for bevacizumab in the USA because the weight of evidence shows no significant survival benefit. Other targeted agents should not be used either in addition to, or as a replacement for, chemotherapy in this setting outside of a trial.

Qualifying Statement: Bevacizumab added to single agent chemotherapy improves response and progression-free survival but not overall survival.
The benefit is improved disease control (potential benefit: moderate). The potential harm is unique toxicity, increased costs, and barriers to access (potential harm: high).
High, supported by multiple trials
Moderate, based on both evidence and expert consensus

Recommendation 4: No single agent has demonstrated superiority in the treatment of patients with advanced breast cancer and there are several active agents appropriate for first-line chemotherapy.
The evidence for efficacy is strongest for taxanes and anthracyclines. Other options include capecitabine, gemcitabine, platinum-based compounds, vinorelbine, and ixabepilone.
Treatment selection should be based on previous therapy, differential toxicity, comorbid conditions, and patient preferences.
Specifically, drugs for which clinical resistance has already been shown should not be reused.
The benefit is a patient-tailored approach with potential improvements in disease control and quality of life (potential benefit: high). The harm is the potential use of a less-active agent (potential harm: low).
The evidence quality supporting the activity of a number of single agents is high, but there is insufficient evidence to support superiority of any single agent
Strong, based on the available evidence and expert consensus

Recommendation 5: Chemotherapy should be continued until progression of disease as tolerated because it modestly improves overall survival and substantially improves progression-free survival, but this has to be balanced against toxicity and quality of life. Short breaks, flexibility in scheduling, or a switch to endocrine therapy (in patients with hormone receptor positive disease) may be offered to selected patients.

Qualifying Statement. It is recognized that the balance between continuing treatment to maintain disease control and coping with progressive side effects/toxicity is a difficult one.
It will be influenced by many factors including drug used (e.g. long term use of capecitabine is relatively easy whereas docetaxel is severely limited by cumulative toxicity) and requires a continuing dialogue between doctor and patient.
The benefits are more time before disease-progression and modestly improved survival (potential benefit: high). The harm is more prolonged toxicity (potential harm: moderate).
High, based on a systematic review with meta-analysis
Strong, supported by evidence and expert consensus

Recommendation 6: Chemotherapy regimens should not be specifically tailored to different breast cancer subtypes (e.g. triple negative, lobular) at the present time due to the absence of evidence proving differential efficacies. In addition, in vitro chemoresistance assays should not be used to select treatment.

Qualifying Statement: This recommendation will need to be modified if ongoing or future research addressing this important issue suggests benefits of tailoring The benefits are not omitting potentially efficacious treatment and cost-saving on in vitro assays (potential benefit: high)
Current evidence shows no convincing basis for either of these approaches
Moderate, supported by expert consensus

Recommendation 7: Second and later-line therapy may be of clinical benefit and should be offered as determined by previous treatments, toxicity, co-existing medical conditions and patient choice. As with first-line treatment, no clear evidence exists for the superiority of one specific drug or regimen. Active agents include those active in first-line.

Qualifying Statement. The most convincing data are for eribulin based on survival superiority against best standard treatment in a recent large RCT, but there are a lack of good comparative data between these various agents The benefit is further chance of disease control and symptomatic improvement (potential benefit: high). The harm is toxicity (potential harm: high)
Ranges from high to low as reported in multiple randomized trials
Strong, based on expert consensus

Recommendation 8: Palliative care should be offered throughout the continuum of care. As there are diminishing returns with later lines of chemotherapy, clinicians should also offer best-supportive care without further chemotherapy as an option.

Qualifying Statement: Evidence suggests that response to second and subsequent lines of chemotherapy is strongly influenced by response to earlier treatment; patients whose disease has failed to respond to up to two initial lines of treatment are less likely to respond to a 3rd or subsequent line. The benefits include a patient-centered approach emphasizing quality of life (potential benefit: high). The main harm is fear of abandonment and giving up hope that can be addressed by effective communication and appropriate end of life planning (potential harm: moderate). Intermediate, supported by several RCTs in patients with advanced cancer
Strong, supported by evidence, expert consensus, and another independent expert consensus

As there is no cure yet for patients with advanced breast cancer, clinicians should encourage all eligible patients to enroll in clinical trials.
This should include the option of Phase 2 and even targeted Phase 1 trials before all standard lines of therapy have been used, in the absence of immediately life-threatening disease.
The benefits are more patients will be directed to clinical studies providing treatment benefits to them and the medical community will benefit from more research to improve treatments available and on which to make treatment decisions. The potential harm is patients will receive inferior treatment
There is no strong evidence to suggest this approach might impair outcome
Strong, based on expert consensus